LENSAR

LNSR · NASDAQ

$5.81+$0.06 (+1.04%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $5.75

LNSR analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $11.22 (+93.1% upside)

Low: $9.09
Now: $5.81
High: $13.65

Upgrades and downgrades

The latest rating actions, newest first

LNSR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
LUCID CAPITAL MARKETS	Sep 28, 2026	Initiates	Buy	$11.00	43%
BTIG	Aug 20, 2026	Maintains	Buy	$9.00 → $10.00	48%
BTIG	Aug 13, 2026	Maintains	Buy	$7.00 → $9.00	48%
BTIG	Mar 18, 2026	Upgrade	Neutral → Buy	$10.00	48%

The case for and against

Updated Sep 5, 2026

Bull case

LENSAR is making significant strides in the ophthalmic medical device market with their femtosecond laser system for cataract surgery. With strong financials and a growing install base, they are well-positioned for continued success. The failed acquisition by Alcon may provide an opportunity for other companies to respond and potentially lead to increased competition in the market. However, we believe that LENSAR's innovative technology and focus on recurring revenue will drive future growth and justify a higher valuation compared to its peers.

Bear case

LENSAR is facing significant challenges in the market and its future revenue streams due to lower growth projections and higher operating spend. With flat revenue in FY26 and further decline in FY27 and FY28, their ALLY pricing changes and thinner margins will make it difficult for them to remain competitive in the ophthalmic industry. Despite a strong initial performance, the terminated acquisition by ALC and the need for a priority credit line agreement to stay afloat raises concerns about their ability to continue operations in the long term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.